MedPath

Neuroscience Trials Australia

Neuroscience Trials Australia logo
๐Ÿ‡ฆ๐Ÿ‡บAustralia
Ownership
Private
Established
2001-01-01
Employees
51
Market Cap
-
Website
https://neurosciencetrialsaustralia.com

Clinical Trials

12

Active:0
Completed:10

Trial Phases

3 Phases

Phase 2:8
Phase 3:3
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (12 trials with phase data)โ€ข Click on a phase to view related trials

Phase 2
8 (66.7%)
Phase 3
3 (25.0%)
Not Applicable
1 (8.3%)

DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval Versus Standard Bridging Thrombolysis With Endovascular Clot Retrieval

Phase 3
Completed
Conditions
Ischemic Stroke
First Posted Date
2018-04-11
Last Posted Date
2022-06-16
Lead Sponsor
Neuroscience Trials Australia
Target Recruit Count
295
Registration Number
NCT03494920
Locations
๐Ÿ‡ฆ๐Ÿ‡บ

Liverpool Hospital, Liverpool, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

John Hunter Hospital, New Lambton, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Royal North Shore Hospital, St Leonards, New South Wales, Australia

and more 30 locations

STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

Phase 2
Completed
Conditions
Intracerebral Haemorrhage
Interventions
Drug: Normal saline
First Posted Date
2017-12-29
Last Posted Date
2023-09-28
Lead Sponsor
Neuroscience Trials Australia
Target Recruit Count
201
Registration Number
NCT03385928
Locations
๐Ÿ‡ฆ๐Ÿ‡บ

Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Liverpool Hospital, Liverpool, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

John Hunter Hospital, New Lambton Heights, New South Wales, Australia

and more 22 locations

Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)

Phase 2
Completed
Conditions
Ischemic Stroke
Interventions
First Posted Date
2017-11-13
Last Posted Date
2020-03-04
Lead Sponsor
Neuroscience Trials Australia
Target Recruit Count
300
Registration Number
NCT03340493
Locations
๐Ÿ‡ฆ๐Ÿ‡บ

Albury Hospital, Albury, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Campbelltown Hospital, Campbelltown, New South Wales, Australia

and more 25 locations

Trial of EXenatide in Acute Ischaemic Stroke

Phase 2
Conditions
Acute Ischemic Stroke
Interventions
First Posted Date
2017-09-19
Last Posted Date
2021-09-14
Lead Sponsor
Neuroscience Trials Australia
Target Recruit Count
350
Registration Number
NCT03287076
Locations
๐Ÿ‡ฆ๐Ÿ‡บ

St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Liverpool Hospital, Liverpool, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Sunshine Coast University Hospital, Birtinya, Queensland, Australia

and more 12 locations

Deferiprone to Delay Dementia (The 3D Study)

Phase 2
Completed
Conditions
Mild Cognitive Impairment
Prodromal Alzheimer's Disease
Mild Alzheimer's Disease
Interventions
First Posted Date
2017-07-31
Last Posted Date
2024-07-03
Lead Sponsor
Neuroscience Trials Australia
Target Recruit Count
81
Registration Number
NCT03234686
Locations
๐Ÿ‡ฆ๐Ÿ‡บ

KaRa Institute of Neurological Diseases, Macquarie Park, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Hunter New England Local Health District, Waratah, New South Wales, Australia

๐Ÿ‡ฆ๐Ÿ‡บ

Box Hill Hospital, Box Hill, Victoria, Australia

and more 5 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.